Remove 2017 Remove Communication Remove Documentation
article thumbnail

FDA Publishes Its Draft Strategy Document on Innovative Manufacturing Technologies

The FDA Law Blog

FDA-2024-N-3945 ] announcing the publication of a draft strategy document, for public comment, outlining specific actions FDA plans to take to facilitate the use of innovative manufacturing technologies. It was at this workshop that the agency committed to issuing a draft strategy document, for public comment.

article thumbnail

Maximizing the MTPC Framework for Current and Future Pharmacists

PQA

In documentation of the care provided, the MTP Categories Framework promotes consistent identification of MTPs found and the interventions taken to resolve MTPs within MTM services. It is clear to me that this rational approach is vital for practice standardization and documentation. Updated August 2017. Third ed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA suggests ways to curb constraints with rare disease gene therapy trials

Pharmaceutical Technology

In 2020, the FDA released a guidance document for the industry with recommendations for sponsors developing gene therapies for rare diseases. This document delved into aspects related to manufacturing, preclinical, and clinical trial design for all phases of clinical development.

FDA 105
article thumbnail

FDA’s Pre-Cert Pilot Ends. Will there be a Sequel?

The FDA Law Blog

Lenz, Principal Medical Device Regulation Expert — FDA began the Software Precertification (Pre-Cert) pilot program in 2017 to evaluate an alternative approach to regulation of software as a medical device (SaMD) over the total product lifecycle (TPLC). By Adrienne R. Key Performance Indicators.

FDA 72
article thumbnail

What is step therapy?

The Checkup by Singlecare

A study by the Johns Hopkins Bloomberg School of Public Health found that few health insurance plans used step therapy for opioids in 2017, which may have contributed to the opioid epidemic. However, in some cases, not requiring step therapy has led to detrimental results.

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

In 2020, the Federal Trade Commission issued a report regarding settlements reached between brand and generic manufacturers in FY 2017 and noted that “for the first time since [FY] 2004, no settlement agreement in [FY] 2017 contains a no-[authorized generic] AG commitment.”. Gilenya is an oral medication for multiple sclerosis.

article thumbnail

Time to change the channel? The future for customer engagement models

pharmaphorum

While remote communication with HCPs rose in all countries in the same time period, not all remote engagement was the type likely to be described as meaningful – much of the volume was in emails, with WhatsApp, and other remote messaging, also important during the peak infection period. In the US, the trend had already started pre-COVID-19.